Biliary anastomosis using T-tube versus no T-tube for liver transplantation in adults.

Cochrane Database Syst RevSep 22, 2026 (epub)
Clinical ResearchGeneral SurgeryCardiothoracic Surgery

Jose Jeova de Oliveira Filho, Rachel Riera, Diego R Kleinubing et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of T-tube use during biliary anastomosis in liver transplantation among 844 adults. The study found that while T-tube use did not significantly affect all-cause mortality (RR 0.98), it may reduce the incidence of anastomotic biliary stenosis (RR 0.33), indicating potential benefits in managing biliary complications.

Key findings

  • T-tube use did not significantly affect all-cause mortality (RR 0.98, 95% CI 0.58 to 1.63).
  • T-tube use may reduce anastomotic biliary stenosis (RR 0.33, 95% CI 0.15 to 0.71).
  • The evidence regarding anastomotic bile leak was also uncertain (RR 0.79, 95% CI 0.37 to 1.69).
  • The review included six RCTs with a total of 844 participants.

Why it matters

Understanding the role of T-tubes in biliary anastomosis can help clinicians make informed decisions regarding surgical techniques in liver transplantation, potentially improving patient outcomes related to biliary complications.

Source

PubMed · PMID 42770372

Published in Cochrane Database Syst Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.